铂类抗肿瘤药物作用机制研究进展  

Recent Research in Antitumor Mechanism of Platinum-Based Drugs

作　　者：高传柱[1] 王天帅[1] 陈佳[1] 费凡[1] 杨波[1] 杨健[1] 廖霞俐[1] 

机构地区：[1]昆明理工大学生命科学与技术学院,云南昆明650500

出　　处：《昆明理工大学学报（自然科学版）》2014年第4期83-92,共10页Journal of Kunming University of Science and Technology(Natural Science)

基　　金：国家自然科学基金项目(21361014;21302074;21062009);教育部博士点基金项目(20125314120007);云南省自然科学基金(人培)项目(KKSY201226108)

摘　　要：因为作用机制独特、抗肿瘤效果显著、抗肿瘤谱广等特点,铂类药物在恶性肿瘤的临床治疗中得到广泛应用.然而,已上市的铂类抗肿瘤药物在各类癌种的治疗过程中也存在着一定的局限性,暨在不同的实体瘤治疗中出现不同程度的毒副反应、耐药性或交叉耐药性等表现.目前,国内外关于铂类药物作用机制的报道较多,通过对已有研究的总结和梳理,不仅能够加强对这类特殊药物作用机制的认识,指导临床用药,而且能够为设计合成出疗效更佳、毒副作用更小、耐药程度更低的新型铂类抗肿瘤药物提供指导.本文就目前关于铂类药物抗肿瘤作用机制的国内外研究进展进行了综述.As one of the most important anticancer drugs with unique anticancer mechanism,high activity and broad anticancer spectrum,platinum-based drugs have been widely used in treatment of malignant tumors. However,the clinical application of platinum-based drugs has been greatly limited by its side effects,resistance or cross-resistance.Summarizing reported researches about anticancer mechanism of platinum-based drugs could deepen the understanding of the special anticancer mechanisms,provide directions in the clinical medication and give more information in designing and synthesizing novel platinum-based drugs with better efficiency,lower toxicity and less resistance.The research progress of platinum compounds for their anticancer mechanisms are therefore summarized in this paper.

关 键 词：铂抗肿瘤药物 抗肿瘤机制 研究进展 

分 类 号：R730.35[医药卫生—肿瘤]